Biotechnology

Faron Announces Five ASH 2026 Abstracts Spanning Bexmarilimab, Clever-1 and Higher-Risk MDS Outcomes

November 4, 2026 9:35 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that five abstracts spanning its bexmarilimab program, Clever-1 biology and outcomes in higher-risk myelodysplastic syndrome (HR-MDS) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual...

Read more

Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance

November 4, 2026 9:20 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that the Company's research examining a mechanism of resistance to CAR T-cell therapy and the potential of DNase I to reverse this process has been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual...

Read more

Nomination Committee Appointed in Respect of AGM 2027 in Alligator Bioscience AB

November 3, 2026 9:20 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), today announced that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 6 May 2027 has been appointed. Pursuant to the instruction for the Nomination Committee adopted by the AGM in 2019, the Nomination Committee for the Alligator Bioscience AGM 2027 shall consist of four members, representing the three largest shareholders at the last weekday of June, together with the...

Read more

Vicore Announces the Nomination Committee for the 2027 Annual General Meeting

November 3, 2026 2:20 AM

Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM). The three largest shareholders as of August 31, 2026, have each appointed a member to the Committee. The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan...

Read more

Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

November 2, 2026 11:25 PM

Impact Biomedical Inc. (NYSE American:IBO) ("Impact" or the "Company") and Zoar Limited (f/k/a Dr. Ashley's Limited) ("PubCo") announced that the U.S. Securities and Exchange Commission ("SEC") declared effective on October 23, 2026, PubCo's registration statement on Form F-4 (the "Registration Statement") in connection with the previously announced business combination involving Impact, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley's Bio Labs...

Read more

OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover

November 2, 2026 11:05 AM

OSR Health, Inc. (OTC PINK:OSRH) ("OSR Health" or the "Company") today announced that its Board of Directors has authorized management to pursue a sale of the Company's controlling interest in OSR Holdings Co., Ltd. ("OSRK") to an undisclosed Nasdaq-listed counterparty ("Acquirer") for a potential reverse takeover. The Proposed Transaction The total value of the contemplated transactions, including the proposed earn-out scheme for OSRH, would be...

Read more

enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

November 2, 2026 8:43 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it will present its investigational enVVe System® at the 38th annual Transcatheter Cardiovascular Conference (TCT®) in San Diego, CA. The presentation, titled "Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve," will be delivered by Rob Berman, Chief Executive Officer of enVVeno Medical, during the...

Read more

Microbix Attending & Presenting at EMMD 2026

November 2, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending EMMD and presenting about optimal usages of its innovative quality assessment products ("QAPs™") for supporting point-of-need or lab-based molecular (e.g., PCR) tests for the diagnosis of infectious diseases. The 2026 EMMD is the 14th European Meeting on Molecular Diagnostics, taking place in...

Read more

Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference

November 2, 2026 2:20 AM

Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the following upcoming healthcare conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Location: InterContinental Boston, Boston Format: Fireside chat and 1×1 meetings Date and time: Monday, November 9, 2026, 8:00-8:25 AM ET...

Read more

Alligator Bioscience Signs Agreement To Sell Mitazalimab to Biossil

October 31, 2026 8:35 AM

Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody program HLX22, today announced that it has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil Inc. ("Biossil"). Alligator will receive USD 0.75 million upfront and is eligible for up to USD 108 million in milestone payments, as...

Read more

enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study

October 30, 2026 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the third quarter ended September 30, 2026. Cash and investments at the end of the quarter were $18.5 million, with a quarterly burn of approximately $3 million. The Company is on track to begin Part 1 of the TAVVE® U.S. pivotal study for its enVVe® system, a first-in-class, non-surgical replacement venous valve, in the fourth...

Read more

Change in Number of Shares and Votes in Alligator Bioscience AB

October 30, 2026 4:20 AM

Alligator Bioscience (STO:ATORX) - During October 2026, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has increased as a result of the rights issue of units which was resolved by the Board of Directors on 23 July 2026 and approved by the extraordinary general meeting on 26 August 2026. As of 30 October 2026, the total number of outstanding shares and votes in Alligator Bioscience amounts to 3,568,106,848,...

Read more

TeselaGen and Tecnológico de Monterrey Announce Collaboration to Advance AI-Driven Scientific Research

October 29, 2026 10:45 AM

TeselaGen, a leading provider of AI-enabled software for the design and execution of biological research, today announced a multi-year collaboration agreement with Tecnológico de Monterrey (TEC), one of Latin America's most prestigious and innovative research institutions. The collaboration aims to accelerate scientific discovery through the use of advanced biological design tools and artificial intelligence, empowering researchers at TEC to...

Read more

Synexis and Nieser Expand Continuous Pathogen Control Across a Region of South America's Poultry Industry

October 29, 2026 9:55 AM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, announced a strategic collaboration with Nieser, a family-owned biosecurity company with more than 30 years of experience supporting intensive animal production. This collaboration will expand access to Synexis patented DHP® technology in Argentina, Uruguay and Paraguay, giving poultry producers an added layer of biosecurity to continuously address microbial...

Read more

AminoShift Research LLC Launches Research-Materials Platform with Per-Lot Documentation and Public Batch Verification

October 29, 2026 8:30 AM

AminoShift Research LLC ("AminoShift"), a Texas supplier of research materials for laboratories and qualified researchers, today announced the launch of its platform at aminoshift.com. The platform organizes materials by research area and attaches a documentation record to each lot, which anyone can look up through a public batch-verification tool before placing an order. "Researchers are usually asked to trust a label," said Lyth Elkour,...

Read more

Bio Essence Unveils Practitioner-Controlled Knowledge Vault, Tackling AI's Trust Barrier in Healthcare

October 29, 2026 8:00 AM

Bio Essence Corporation (OTCQB:BIOE) ("Bio Essence" or the "Company") today announced the completion of a Practitioner Knowledge Vault prototype that lets healthcare practitioners keep control of their professional knowledge instead of surrendering it as generic AI training data. The milestone, which includes full architecture and security/data-flow design, is the first major step in the Company's MediFlow Practitioner AI initiative. The...

Read more

ClearPoint Neuro Reports Third Quarter 2026 Results

October 28, 2026 4:05 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Highlights Reported third quarter revenue of $12.1 million, representing 36% overall growth, including the recently acquired IRRAflow Portfolio; Neurosurgery navigation and therapy,...

Read more

OSR Health Provides Shareholder Update Following Nasdaq Panel Decision

October 28, 2026 9:15 AM

OSR Health, Inc. (OTC PINK:OSRH) ("OSR Health" or the "Company"), a global healthcare holding company, today provided an update to shareholders following the decision of the Nasdaq Hearings Panel to delist the Company's securities from The Nasdaq Stock Market. Nasdaq decision On October 23, 2026, the Nasdaq Hearings Panel determined to delist the Company's securities for non-compliance with Nasdaq's $1.00 minimum bid price requirement. The...

Read more

Microbix Reviews New U.S. Tariffs on Canada

October 28, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is reviewing the effects of recent changes to United States ("U.S.") tariffs on Canada being imposed via Presidential proclamation using provisions of Section 338 of the Smoot-Hawley Tariff Act of 1930 (the "Act"). The Act was intended to protect U.S. industries during the Great Depression and enables the U.S....

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

October 27, 2026 1:35 PM

Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Friday 27 November 2026 at 10:00 CET, at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden. RIGHT TO...

Read more